Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Uncovering the Profile of Somatic mtDNA Mutations in Chinese Colorectal Cancer Patients

  • Cheng-Ye Wang ,

    Contributed equally to this work with: Cheng-Ye Wang, Hui Li

    Affiliation State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China

  • Hui Li ,

    Contributed equally to this work with: Cheng-Ye Wang, Hui Li

    Affiliation State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China

  • Xiao-Dan Hao,

    Affiliations State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China, Graduate School of the Chinese Academy of Sciences, Beijing, China

  • Jia Liu,

    Affiliation Laboratory for Conservation and Utilization of Bio-resource, Yunnan University, Kunming, China

  • Jia-Xin Wang,

    Affiliation Laboratory for Conservation and Utilization of Bio-resource, Yunnan University, Kunming, China

  • Wen-Zhi Wang,

    Affiliations State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China, Graduate School of the Chinese Academy of Sciences, Beijing, China

  • Qing-Peng Kong ,

    zhangyp1@263.net.cn (Y-PZ); kongqp@yahoo.com.cn (Q-PK)

    Affiliations State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China, KIZ/CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming, China

  • Ya-Ping Zhang

    zhangyp1@263.net.cn (Y-PZ); kongqp@yahoo.com.cn (Q-PK)

    Affiliations State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China, Laboratory for Conservation and Utilization of Bio-resource, Yunnan University, Kunming, China, KIZ/CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming, China

Uncovering the Profile of Somatic mtDNA Mutations in Chinese Colorectal Cancer Patients

  • Cheng-Ye Wang, 
  • Hui Li, 
  • Xiao-Dan Hao, 
  • Jia Liu, 
  • Jia-Xin Wang, 
  • Wen-Zhi Wang, 
  • Qing-Peng Kong, 
  • Ya-Ping Zhang
PLOS
x

Abstract

In the past decade, a high incidence of somatic mitochondrial DNA (mtDNA) mutations has been observed, mostly based on a fraction of the molecule, in various cancerous tissues; nevertheless, some of them were queried due to problems in data quality. Obviously, without a comprehensive understanding of mtDNA mutational profile in the cancerous tissue of a specific patient, it is unlikely to disclose the genuine relationship between somatic mtDNA mutations and tumorigenesis. To achieve this objective, the most straightforward way is to directly compare the whole mtDNA genome variation among three tissues (namely, cancerous tissue, para-cancerous tissue, and distant normal tissue) from the same patient. Considering the fact that most of the previous studies on the role of mtDNA in colorectal tumor focused merely on the D-loop or partial segment of the molecule, in the current study we have collected three tissues (cancerous, para-cancerous and normal tissues) respectively recruited from 20 patients with colorectal tumor and completely sequenced the mitochondrial genome of each tissue. Our results reveal a relatively lower incidence of somatic mutations in these patients; intriguingly, all somatic mutations are in heteroplasmic status. Surprisingly, the observed somatic mutations are not restricted to cancer tissues, for the para-cancer tissues and distant normal tissues also harbor somatic mtDNA mutations with a lower frequency than cancerous tissues but higher than that observed in the general population. Our results suggest that somatic mtDNA mutations in cancerous tissues could not be simply explained as a consequence of tumorigenesis; meanwhile, the somatic mtDNA mutations in normal tissues might reflect an altered physiological environment in cancer patients.

Introduction

In the past decade, the role of mitochondrial DNA (mtDNA) mutation in tumorigenesis has received much attention. A high incidence of somatic mtDNA mutations, mostly in homoplastic, has been identified in nearly all types of cancerous tissues [1], [2]. Nonetheless, the relationship of somatic mtDNA mutations and tumorigenesis has been hotly debated. Some studies suggested that the mtDNA somatic mutations likely result from the elevated reactive oxygen species (ROS) in tumor cell [3], [4], [5], because most of these mutations are T to C and G to A base transitions [1], [2], similar to the mutation pattern of oxidative decay on DNA [6], [7]. It was also suggested that some changes in mtDNA could disable the function of mitochondrial respiratory chain and thus contribute to tumor procession [8], [9], [10], [11]. For example, a recent study suggested that mtDNA mutations which produce the deficiency in respiratory complex I activity could contribute to tumor progression by enhancing the metastatic potential of tumor cells [12]. In contrast, some studies suggested that the somatic mutation in tumor tissue could simply arise by chance in tumor progenitor cells without any physiological advantage or tumorigenic requirement [13], [14]. Indeed, Vega and colleagues found that a lot of mtDNA mutations detected in tumor were in fact the common polymorphisms or mutational hotspots prevailing in human general populations, leading the authors to propose that these somatic mutations are more likely to be neutral [15]. Similarly, the functional roles of some of the identified somatic mtDNA mutations were queried largely due to the problems in data quality [16], [17], [18]. Obviously, further evidence is needed to elucidate the exact role that somatic mtDNA mutations have play in tumorigenesis.

In the present study, we performed the whole mitochondrial genome screening for somatic mutation in paired cancerous and non-cancerous tissues from 20 patients with colorectal cancer. By using the same quality control measures as adopted in our previous studies in complete mtDNA sequencing [19], [20], [21], [22], we want to get a deeper insight into the profile of the mtDNA somatic mutations in colorectal cancer. The direct comparison of the entire mtDNA sequences of the primary cancerous, matched para-cancerous normal and distant normal tissues from the same patient, accompanied with the stringent data-quality control, is adopted to disclose a detailed profile of mtDNA somatic mutations in both normal and tumor tissues in the same patient. Our results revealed that the observed somatic mutations in our samples are much less frequent than the previous studies. Surprisingly, all the observed somatic mutations are in heteroplasmic state, an observation quite different from the previous studies.

Result

A total of 59 complete mitochondrial genome sequences of three paired tissues from 20 colorectal cancer patients were obtained in this study, and all the sequences have been deposited into GenBank (http://www.ncbi.nlm.nih.gov/Genbank/) with accession numbers GU392048–GU392106. All the mtDNA variable sites of each tissue have been displayed on a schematic tree (Figure 1), which could provide a direct comparison of the entire mtDNA genome variation among three tissues from the same patient and thus allow pinpointing the somatic mutation(s) in a patient conveniently. As demonstrated in Figure 1, six of 20 patients carried mtDNA somatic mutations in their cancerous tissues, occupying a much lesser proportion (6/20; 30%) than many previous reports. For example, Tan et al. found 27 somatic mutations in 14/19 (74%) breast patients [23]; Zhu et al. found 45 somatic mutations at 35 nucleotide position in 14/15 (93%) breast cancer patients [24]; in Polyak et al. (1998), 7/10 (70%) colorectal tumor cases were demonstrated to carry one to three mutations.

thumbnail
Figure 1. Phylogenetic tree of 59 complete mtDNA sequences from colorectal normal and malignant tissues.

Haplogroup names are inserted along the branches determining the locations of the corresponding ancestral haplotypes. Variants (reconstructed most parsimoniously) on uninterrupted branches are listed arbitrarily in ascending order. Suffixes “A, C and T” indicate transversions, “ins” indicates a nucleotide insertion; “C/T, A/C, and A/G” suggest heteroplasmic mutations, “d” indicates a deletion. Recurrent variants are underlined. Length variation of C-tract around positions 310 and 16189 is not indicated in the figure. Suffixes “C, CP, and CN” in the sample names indicate “cancerous tissue, para-cancerous tissue and normal tissue” respectively.

https://doi.org/10.1371/journal.pone.0021613.g001

In total, there are 18 somatic mutations were detected in the 59 tissue samples under study (Figure 1 and Table S1), and all the somatic mutations occur merely on the terminal branches of phylogenic tree, and no haplotype-shift was observed. With the exception of the RNA-coding genes (including sRNA and tRNA), these somatic mutation sites are dispersed across the entire mtDNA genome, which seems quite different from the mutation spectrum observed in patients with mitochondrial diseases [25], [26]. Specifically, seven mutations locate in the D-loop region, whereas the remaining 11 locate in protein-coding regions. Among the 11 coding-region somatic mutations, only two (i.e., G4532A and A9275G) are synonymous transitions which occur on two unstable sites; whereas the rest nine mutations all are non-synonymous substitutions that locate at positions 6718, 14288, 15332, 15447, and 15276, most of which are evolutionarily highly conserved after compared with the mitochondrial genomes from 13 different vertebrate species (Table S1). By further evaluating the conservation of these five mutational sites among a total of published 3,635 complete mitochondrial genome sequences from general human populations, our results revealed that all of the five sites are highly conserved among the general human populations as well (Table S1). Surprisingly, in spite of the high conservation of site 6718, heteroplasmic variation 6718A/G presents in both the cancer and the para-cancer normal tissues of Patient 1, raising the possibility that the para-cancer normal tissue has likely been invaded by cancer cells. Indeed, a similar pattern is observed in Patient 3, in which its cancer and para-cancer tissues share the same heteroplasmic variation 16365C/T. This observation, again, emphasizes the particular necessity of the inclusion of the distant normal tissue for analysis.

Intriguingly, as shown in Figure 1, the pinpointed mtDNA somatic mutations are not restricted merely to tumor tissues, for we did have observed some somatic mutations in the normal tissues of Patients 1, 3, 8, 14, and 20. Specifically, transition 14288 seems to be a recurrent mutation site because it appears in three patients belonging to different haplogroups. This non-synonymous mutation presents only in normal tissues of the patients. The 14288 site itself is not conserved across different species but seems to be quite conserved among human populations; whether this mutation has functional effect is unknown.

In Patient 14, site 16093 in cancerous tissue is homoplastic C, while in para-cancerous normal and distant normal tissue this site shifts to be heteroplasmic as C/T. This pattern was confirmed by DHPLC assay result: in cancerous tissue C14 site 16093 displays a single peak, whereas in para-cancerous normal and distant normal tissues it shows double peak (Figure 2). Of note is that site 16093 itself is a hot spot in the general population and mutation on this site has also been found in normal tissue of cancer patients in other studies [27]. Similar phenomenon also happened to Patient 20, in which only distant normal tissue harbored somatic mutation (viz., A9275G). These mtDNA somatic mutations might be irrelevant to tumorigenesis considering their appearance in the normal tissues.

thumbnail
Figure 2. DHPLC assay of the heteroplasmic somatic mutations.

Direct sequencing demonstrate that nucleotide site 16093 displays a homoplastic C in cancerous tissue, while in para-cancer normal and distant normal tissue this site is in heteroplasmic status of T/C. DHPLC assay confirmed the sequencing result: in tissue C14 it displays a single peak, whereas in CP14 and CN14 it shows double peak.

https://doi.org/10.1371/journal.pone.0021613.g002

Discussion

Hitherto, most of the previous studies on the role of mtDNA in colorectal tumor focused merely on the D-loop or partial segment of the molecule [28], [29], [30], [31], only a few reports have focused on the mutational profile on its whole genome (Polyak et al. 1998). To get more insights into the relationship between mtDNA and colorectal tumor, in the current study we have recruited three tissues (cancerous, para-cancerous and normal tissues) sampled from 20 patients with colorectal tumor; by sequencing the entire mtDNA genome from each tissue and comparing the mutational difference among three tissues from the same patient, our study revealed a relatively low mutational frequency and the heteroplasmic status of all the observed somatic mutations. These observations are quite different from the previous studies, emphasizing the complexity in the etiology of colorectal tumor.

Since most of the patients (12/20) under study do not harbor any mtDNA somatic mutation in their cancerous tissues, one explanation could be that it is the modification in nuclear genome which has contributed to the tumorigenesis in the samples without involving any mtDNA changes. The frequency of mtDNA somatic mutations (6/20; 30%) observed in our current study, which is comparable to our previous results on breast cancer (2/10; 20% [22]), but is significantly lower (p<0.05) than the previous observations, especially those on colorectal tumor. For example, Polyak et al. found that 7/10 (70%) colorectal tumor patients carried one to three mutations [32]. It is possible that the somatic mutation frequency may vary among different ethnic populations or correlate with the cancer stages; testing this possibility would require a systematic design of the study in near future. Alternatively, the much lower incidence of somatic mutations observed in our study is most plausibly attributed to the stringent quality control that was adopted during the data generation and analysis. Indeed, when the potential problems pinpointed in the earlier studies by using a phylogenetic approach [18] were excluded, the frequency of somatic mutations would then decrease considerably.

Intriguingly, all the somatic mutations identified here are in heteroplasmic, which is quite different from the previous observations. Especially, some of the somatic heteroplasmic mutation also present in the normal tissues of the cancer patients. Similarly, Taylor and colleagues also found mtDNA somatic mutations in the normal tissue in colorectal tumor patients, and most of these mutations were heteroplasmic [33]. To evaluate whether the heteroplasmic mtDNA somatic mutations detected in the normal tissues of cancer patients is a normal phenomenon, we investigated the frequency of heteroplasmic mtDNA somatic mutations in the general human populations (embracing a total of 4738 mtDNA genome sequences retrieved from the literature). Our result revealed that the frequency of individuals harboring heteroplasmic somatic mtDNA mutation(s) is less than 4%, suggesting that heteroplasmy in mtDNA from the general population is a rare phenomenon, at least when detected by direct DNA sequencing method [34], [35], [36]. Then we thoroughly reviewed the previous studies on mtDNA mutation in different tumor types and found that heteroplasmic somatic mtDNA mutations were also observed in the normal tissues of cancer patients [9], [22], [27], [33], [37], with a significant higher frequency (38.6%) than in the general population (3.2%; p<0.001) but still lower than that in the cancerous tissue (52.9%; p<0.05) (Table S2). Since each individual is characterized by a mixture of related mitochondrial haplotypes, and widespread heteroplasmy in the mtDNAs of various normal human tissues does have been observed [27], [38], [39], [40]. It is likely that the observed difference in the frequencies of the heteroplasmic mutations between the normal tissue of tumor patients and the general population (commonly adopting their peripheral blood) is attributed to the heteroplasmy between different tissues. Alternatively, the increased heteroplasmic mutation frequency, in both cancerous and matched normal tissues in tumor patients relative to the general population (Table S2), might result from an altered physiological environment (maybe the elevated level of ROS, or some other unknown mutagens). For instance, Goodwin et al. (2008) found that both tumor and matched normal tissues from prostate cancer patients exhibit significantly higher expression of spermine oxidase [41], which has been linked to increased ROS and DNA damage [42], [43], versus tissues from prostate disease-free patients.

In retrospect, previous studies have demonstrated that mtDNA mutation with potential functional effect could contribute to tumor procession [8], [12]. In the present study, the identified somatic mtDNA mutations in coding region all located in evolutionarily highly conserved sites. Therefore, it seems possible that these somatic mutations, albeit all in heteroplasmic, might have played some roles in affecting the function of respiratory chain and thus have some biochemical functional effect to its host cell. However, considering that most of the patients do not harbor somatic mutations in the cancerous tissues, whether the functional effect of these somatic mutations are necessary for the host cell remains unknown. As to the somatic mtDNA mutations present in normal tissues, they should reflect an altered microenvironment for the mtDNA. Whether these mutations, plus the interaction with the altered microenvironment, could increase the susceptibility for a cell to tumorigenesis is unknown.

In total, understanding the relationship between mtDNA somatic mutations and tumorigenesis is a challenging task, because strategies that directly estimating cell fates or tracing the detailed process of both events are still impractical in vivo. By direct comparing mtDNA genome variation in three paired tissues from the same patient, our study could provide an extensive profile of the somatic mtDNA mutation in tumor patient. A low frequency somatic mtDNA mutation was identified in the colorectal patients and all the mutations were heteroplasmic. Meanwhile, some somatic mutations could be present in the normal tissue which indicates that these somatic mutations are not the consequence of tumorigenesis, and it might reflect a changed physiological environment for the mtDNA in tumor patient.

Materials and Methods

Clinical samples

A total of 59 tissue samples were collected in this study, including the primary colorectal cancerous tissues (C1–C10), corresponding para-cancerous normal tissues (CP1–CP10) and distant normal tissues (CN1–CN10), which were taken from 20 Chinese patients with colorectal cancer during surgery with informed consent. The cancerous tissue was confirmed by HE-stained slides of the frozen section after surgery, whereas the para-cancerous normal tissue was obtained from the normal tissue surrounding the cancer, and the distant normal tissue is at least 5 cm away from the edge of the cancer tissue. All the patients were clinically diagnosed with stage I (T1–T2, N0, M0) colorectal cancer according to the clinical standard for the category of the cancer [44]. Since the major objective of our study is to pinpoint the subtle difference between cancer and the matched normal tissues from the viewpoint of mitochondrial genome, only the colorectal normal tissues (including the para-cancerous and distant normal tissues) from the same patient were therefore taken into consideration. The para-cancerous normal tissue was not available for Patient 19. The study was performed according to the Declaration of Helsinki.

DNA amplification and sequencing

Total genomic DNA was respectively extracted from the para-cancerous tissue, primary cancerous tissue and distant normal tissue by using the standard phenol/chloroform method. The entire mtDNA genomes were amplified and sequenced as fully described in our previous studies [19], [20], [21], [22]. Sequencing data were edited and aligned by use of the DNASTAR software (DNAStar Inc., Madison, Wisc.), and mutations were scored relative to the revised Cambridge reference sequence (rCRS) [45]. The phylogenetic status of each mtDNA was determined according to the reconstructed East Asian mtDNA phylogeny [20], [46], and their relationships were illustrated by way of a schematic phylogenetic tree (Figure 1).

Quality control

To avoid potential problems and errors observed in the published mtDNA disease studies [18], [47], [48], [49], a stringent quality-control procedure [19], [20], [21] was utilized in the course of sample handling and data generation. In addition, to fully avoid artificial recombination triggered by sample mix-up or contamination [18], [50], each tissue sample was amplified and sequenced individually as we have done before [22].

Determination of heteroplasmy by DHPLC

For the observed heteroplasmic mutation during the direct DNA sequencing, we further confirmed it by denaturing high-performance liquid chromatography (DHPLC) (Figure 2).

Supporting Information

Table S1.

Somatic mtDNA mutations identified in 20 colorectal patients

https://doi.org/10.1371/journal.pone.0021613.s001

(DOC)

Table S2.

Comparison of the frequency of individuals harboring heteroplasmic mtDNA mutations in normal population and in cancer patients.

https://doi.org/10.1371/journal.pone.0021613.s002

(DOC)

Acknowledgments

We are grateful to all the participants in this research. We also would like to acknowledge Shi-Fang Wu and Chun-Ling Zhu for their help in experiments. We thank the anonymous reviewers for helpful comments on the earlier version of the manuscript.

Author Contributions

Conceived and designed the experiments: Q-PK Y-PZ. Performed the experiments: C-YW HL X-DH JL J-XW. Analyzed the data: C-YW W-ZW. Wrote the paper: C-YW HL Q-PK Y-PZ. Discussed the results and commented on the manuscript: C-YW HL X-DH JL J-XW W-ZW Q-PK Y-PZ. Read and approved the final manuscript: C-YW HL X-DH JL J-XW W-ZW Q-PK Y-PZ.

References

  1. 1. Brandon M, Baldi P, Wallace DC (2006) Mitochondrial mutations in cancer. Oncogene 25: 4647–4662.M. BrandonP. BaldiDC Wallace2006Mitochondrial mutations in cancer.Oncogene2546474662
  2. 2. Chatterjee A, Mambo E, Sidransky D (2006) Mitochondrial DNA mutations in human cancer. Oncogene 25: 4663–4674.A. ChatterjeeE. MamboD. Sidransky2006Mitochondrial DNA mutations in human cancer.Oncogene2546634674
  3. 3. Warburg O (1956) On the origin of cancer cells. Science 123: 309–314.O. Warburg1956On the origin of cancer cells.Science123309314
  4. 4. Chen JZ, Gokden N, Greene GF, Green B, Kadlubar FF (2003) Simultaneous generation of multiple mitochondrial DNA mutations in human prostate tumors suggests mitochondrial hyper-mutagenesis. Carcinogenesis 24: 1481–1487.JZ ChenN. GokdenGF GreeneB. GreenFF Kadlubar2003Simultaneous generation of multiple mitochondrial DNA mutations in human prostate tumors suggests mitochondrial hyper-mutagenesis.Carcinogenesis2414811487
  5. 5. Lim SD, Sun C, Lambeth JD, Marshall F, Amin M, et al. (2005) Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate 62: 200–207.SD LimC. SunJD LambethF. MarshallM. Amin2005Increased Nox1 and hydrogen peroxide in prostate cancer.Prostate62200207
  6. 6. Beckman KB, Ames BN (1997) Oxidative decay of DNA. J Biol Chem 272: 19633–19636.KB BeckmanBN Ames1997Oxidative decay of DNA.J Biol Chem2721963319636
  7. 7. Cadet J, Douki T, Gasparutto D, Ravanat JL (2003) Oxidative damage to DNA: formation, measurement and biochemical features. Mutat Res 531: 5–23.J. CadetT. DoukiD. GasparuttoJL Ravanat2003Oxidative damage to DNA: formation, measurement and biochemical features.Mutat Res531523
  8. 8. Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, et al. (2005) mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S A 102: 719–724.JA PetrosAK BaumannE. Ruiz-PesiniMB AminCQ Sun2005mtDNA mutations increase tumorigenicity in prostate cancer.Proc Natl Acad Sci U S A102719724
  9. 9. Parr RL, Dakubo GD, Crandall KA, Maki J, Reguly B, et al. (2006) Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn 8: 312–319.RL ParrGD DakuboKA CrandallJ. MakiB. Reguly2006Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology.J Mol Diagn8312319
  10. 10. Ohta S (2006) Contribution of somatic mutations in the mitochondrial genome to the development of cancer and tolerance against anticancer drugs. Oncogene 25: 4768–4776.S. Ohta2006Contribution of somatic mutations in the mitochondrial genome to the development of cancer and tolerance against anticancer drugs.Oncogene2547684776
  11. 11. Suissa S, Wang Z, Poole J, Wittkopp S, Feder J, et al. (2009) Ancient mtDNA genetic variants modulate mtDNA transcription and replication. PLoS Genet 5: e1000474.S. SuissaZ. WangJ. PooleS. WittkoppJ. Feder2009Ancient mtDNA genetic variants modulate mtDNA transcription and replication.PLoS Genet5e1000474
  12. 12. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, et al. (2008) ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320: 661–664.K. IshikawaK. TakenagaM. AkimotoN. KoshikawaA. Yamaguchi2008ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis.Science320661664
  13. 13. Coller HA, Khrapko K, Bodyak ND, Nekhaeva E, Herrero-Jimenez P, et al. (2001) High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection. Nat Genet 28: 147–150.HA CollerK. KhrapkoND BodyakE. NekhaevaP. Herrero-Jimenez2001High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection.Nat Genet28147150
  14. 14. Chinnery PF, Samuels DC, Elson J, Turnbull DM (2002) Accumulation of mitochondrial DNA mutations in ageing, cancer, and mitochondrial disease: is there a common mechanism? Lancet 360: 1323–1325.PF ChinneryDC SamuelsJ. ElsonDM Turnbull2002Accumulation of mitochondrial DNA mutations in ageing, cancer, and mitochondrial disease: is there a common mechanism?Lancet36013231325
  15. 15. Vega A, Salas A, Gamborino E, Sobrido MJ, Macaulay V, et al. (2004) mtDNA mutations in tumors of the central nervous system reflect the neutral evolution of mtDNA in populations. Oncogene 23: 1314–1320.A. VegaA. SalasE. GamborinoMJ SobridoV. Macaulay2004mtDNA mutations in tumors of the central nervous system reflect the neutral evolution of mtDNA in populations.Oncogene2313141320
  16. 16. Copeland WC, Wachsman JT, Johnson FM, Penta JS (2002) Mitochondrial DNA alterations in cancer. Cancer Invest 20: 557–569.WC CopelandJT WachsmanFM JohnsonJS Penta2002Mitochondrial DNA alterations in cancer.Cancer Invest20557569
  17. 17. Carew JS, Huang P (2002) Mitochondrial defects in cancer. Mol Cancer 1: 9.JS CarewP. Huang2002Mitochondrial defects in cancer.Mol Cancer19
  18. 18. Salas A, Yao YG, Macaulay V, Vega A, Carracedo A, et al. (2005) A critical reassessment of the role of mitochondria in tumorigenesis. PLoS Med 2: e296.A. SalasYG YaoV. MacaulayA. VegaA. Carracedo2005A critical reassessment of the role of mitochondria in tumorigenesis.PLoS Med2e296
  19. 19. Sun C, Kong QP, Palanichamy MG, Agrawal S, Bandelt HJ, et al. (2006) The dazzling array of basal branches in the mtDNA macrohaplogroup M from India as inferred from complete genomes. Mol Biol Evol 23: 683–690.C. SunQP KongMG PalanichamyS. AgrawalHJ Bandelt2006The dazzling array of basal branches in the mtDNA macrohaplogroup M from India as inferred from complete genomes.Mol Biol Evol23683690
  20. 20. Kong QP, Yao YG, Sun C, Bandelt HJ, Zhu CL, et al. (2003) Phylogeny of east Asian mitochondrial DNA lineages inferred from complete sequences. Am J Hum Genet 73: 671–676.QP KongYG YaoC. SunHJ BandeltCL Zhu2003Phylogeny of east Asian mitochondrial DNA lineages inferred from complete sequences.Am J Hum Genet73671676
  21. 21. Palanichamy MG, Sun C, Agrawal S, Bandelt HJ, Kong QP, et al. (2004) Phylogeny of mitochondrial DNA macrohaplogroup N in India, based on complete sequencing: implications for the peopling of South Asia. Am J Hum Genet 75: 966–978.MG PalanichamyC. SunS. AgrawalHJ BandeltQP Kong2004Phylogeny of mitochondrial DNA macrohaplogroup N in India, based on complete sequencing: implications for the peopling of South Asia.Am J Hum Genet75966978
  22. 22. Wang CY, Wang HW, Yao YG, Kong QP, Zhang YP (2007) Somatic mutations of mitochondrial genome in early stage breast cancer. Int J Cancer 121: 1253–1256.CY WangHW WangYG YaoQP KongYP Zhang2007Somatic mutations of mitochondrial genome in early stage breast cancer.Int J Cancer12112531256
  23. 23. Tan DJ, Bai RK, Wong LJ (2002) Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res 62: 972–976.DJ TanRK BaiLJ Wong2002Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer.Cancer Res62972976
  24. 24. Zhu W, Qin W, Bradley P, Wessel A, Puckett CL, et al. (2005) Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid. Carcinogenesis 26: 145–152.W. ZhuW. QinP. BradleyA. WesselCL Puckett2005Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid.Carcinogenesis26145152
  25. 25. Sternberg D, Chatzoglou E, Laforet P, Fayet G, Jardel C, et al. (2001) Mitochondrial DNA transfer RNA gene sequence variations in patients with mitochondrial disorders. Brain 124: 984–994.D. SternbergE. ChatzoglouP. LaforetG. FayetC. Jardel2001Mitochondrial DNA transfer RNA gene sequence variations in patients with mitochondrial disorders.Brain124984994
  26. 26. Von Kleist-Retzow JC, Schauseil-Zipf U, Michalk DV, Kunz WS (2003) Mitochondrial diseases–an expanding spectrum of disorders and affected genes. Exp Physiol 88: 155–166.JC Von Kleist-RetzowU. Schauseil-ZipfDV MichalkWS Kunz2003Mitochondrial diseases–an expanding spectrum of disorders and affected genes.Exp Physiol88155166
  27. 27. He Y, Wu J, Dressman DC, Iacobuzio-Donahue C, Markowitz SD, et al. (2010) Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature 464: 610–614.Y. HeJ. WuDC DressmanC. Iacobuzio-DonahueSD Markowitz2010Heteroplasmic mitochondrial DNA mutations in normal and tumour cells.Nature464610614
  28. 28. Mehrabi S, Akwe JA, Adams G Jr, Grizzle W, Yao X, et al. (2010) Analysis of mtDNA sequence variants in colorectal adenomatous polyps. Diagn Pathol 5: 66.S. MehrabiJA AkweG. Adams JrW. GrizzleX. Yao2010Analysis of mtDNA sequence variants in colorectal adenomatous polyps.Diagn Pathol566
  29. 29. Akouchekian M, Houshmand M, Hemati S, Ansaripour M, Shafa M (2009) High rate of mutation in mitochondrial DNA displacement loop region in human colorectal cancer. Dis Colon Rectum 52: 526–530.M. AkouchekianM. HoushmandS. HematiM. AnsaripourM. Shafa2009High rate of mutation in mitochondrial DNA displacement loop region in human colorectal cancer.Dis Colon Rectum52526530
  30. 30. Hibi K, Nakayama H, Yamazaki T, Takase T, Taguchi M, et al. (2001) Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients. Int J Cancer 94: 429–431.K. HibiH. NakayamaT. YamazakiT. TakaseM. Taguchi2001Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients.Int J Cancer94429431
  31. 31. Lievre A, Chapusot C, Bouvier AM, Zinzindohoue F, Piard F, et al. (2005) Clinical value of mitochondrial mutations in colorectal cancer. J Clin Oncol 23: 3517–3525.A. LievreC. ChapusotAM BouvierF. ZinzindohoueF. Piard2005Clinical value of mitochondrial mutations in colorectal cancer.J Clin Oncol2335173525
  32. 32. Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, et al. (1998) Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 20: 291–293.K. PolyakY. LiH. ZhuC. LengauerJK Willson1998Somatic mutations of the mitochondrial genome in human colorectal tumours.Nat Genet20291293
  33. 33. Taylor RW, Barron MJ, Borthwick GM, Gospel A, Chinnery PF, et al. (2003) Mitochondrial DNA mutations in human colonic crypt stem cells. J Clin Invest 112: 1351–1360.RW TaylorMJ BarronGM BorthwickA. GospelPF Chinnery2003Mitochondrial DNA mutations in human colonic crypt stem cells.J Clin Invest11213511360
  34. 34. Santos C, Montiel R, Arruda A, Alvarez L, Aluja MP, et al. (2008) Mutation patterns of mtDNA: empirical inferences for the coding region. BMC Evol Biol 8: 167.C. SantosR. MontielA. ArrudaL. AlvarezMP Aluja2008Mutation patterns of mtDNA: empirical inferences for the coding region.BMC Evol Biol8167
  35. 35. Santos C, Montiel R, Sierra B, Bettencourt C, Fernandez E, et al. (2005) Understanding differences between phylogenetic and pedigree-derived mtDNA mutation rate: a model using families from the Azores Islands (Portugal). Mol Biol Evol 22: 1490–1505.C. SantosR. MontielB. SierraC. BettencourtE. Fernandez2005Understanding differences between phylogenetic and pedigree-derived mtDNA mutation rate: a model using families from the Azores Islands (Portugal).Mol Biol Evol2214901505
  36. 36. Bendall KE, Macaulay VA, Baker JR, Sykes BC (1996) Heteroplasmic point mutations in the human mtDNA control region. Am J Hum Genet 59: 1276–1287.KE BendallVA MacaulayJR BakerBC Sykes1996Heteroplasmic point mutations in the human mtDNA control region.Am J Hum Genet5912761287
  37. 37. Greaves LC, Preston SL, Tadrous PJ, Taylor RW, Barron MJ, et al. (2006) Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. Proc Natl Acad Sci U S A 103: 714–719.LC GreavesSL PrestonPJ TadrousRW TaylorMJ Barron2006Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission.Proc Natl Acad Sci U S A103714719
  38. 38. Osborne A, Reis AH, Bach L, Wangh LJ (2009) Single-molecule LATE-PCR analysis of human mitochondrial genomic sequence variations. PLoS One 4: e5636.A. OsborneAH ReisL. BachLJ Wangh2009Single-molecule LATE-PCR analysis of human mitochondrial genomic sequence variations.PLoS One4e5636
  39. 39. White HE, Durston VJ, Seller A, Fratter C, Harvey JF, et al. (2005) Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing. Genet Test 9: 190–199.HE WhiteVJ DurstonA. SellerC. FratterJF Harvey2005Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing.Genet Test9190199
  40. 40. Grzybowski T (2000) Extremely high levels of human mitochondrial DNA heteroplasmy in single hair roots. Electrophoresis 21: 548–553.T. Grzybowski2000Extremely high levels of human mitochondrial DNA heteroplasmy in single hair roots.Electrophoresis21548553
  41. 41. Goodwin AC, Jadallah S, Toubaji A, Lecksell K, Hicks JL, et al. (2008) Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. Prostate 68: 766–772.AC GoodwinS. JadallahA. ToubajiK. LecksellJL Hicks2008Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues.Prostate68766772
  42. 42. Babbar N, Casero RA Jr (2006) Tumor necrosis factor-alpha increases reactive oxygen species by inducing spermine oxidase in human lung epithelial cells: a potential mechanism for inflammation-induced carcinogenesis. Cancer Res 66: 11125–11130.N. BabbarRA Casero Jr2006Tumor necrosis factor-alpha increases reactive oxygen species by inducing spermine oxidase in human lung epithelial cells: a potential mechanism for inflammation-induced carcinogenesis.Cancer Res661112511130
  43. 43. Xu H, Chaturvedi R, Cheng Y, Bussiere FI, Asim M, et al. (2004) Spermine oxidation induced by Helicobacter pylori results in apoptosis and DNA damage: implications for gastric carcinogenesis. Cancer Res 64: 8521–8525.H. XuR. ChaturvediY. ChengFI BussiereM. Asim2004Spermine oxidation induced by Helicobacter pylori results in apoptosis and DNA damage: implications for gastric carcinogenesis.Cancer Res6485218525
  44. 44. Sobin LHWC, editor. (2002) TNM classification of malignant tumors. New York: Wiley-Liss. LHWC Sobin2002TNM classification of malignant tumorsNew YorkWiley-Liss
  45. 45. Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, et al. (1999) Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat Genet 23: 147.RM AndrewsI. KubackaPF ChinneryRN LightowlersDM Turnbull1999Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA.Nat Genet23147
  46. 46. Kong QP, Bandelt HJ, Sun C, Yao YG, Salas A, et al. (2006) Updating the East Asian mtDNA phylogeny: a prerequisite for the identification of pathogenic mutations. Hum Mol Genet 15: 2076–2086.QP KongHJ BandeltC. SunYG YaoA. Salas2006Updating the East Asian mtDNA phylogeny: a prerequisite for the identification of pathogenic mutations.Hum Mol Genet1520762086
  47. 47. Bandelt HJ, Lahermo P, Richards M, Macaulay V (2001) Detecting errors in mtDNA data by phylogenetic analysis. Int J Legal Med 115: 64–69.HJ BandeltP. LahermoM. RichardsV. Macaulay2001Detecting errors in mtDNA data by phylogenetic analysis.Int J Legal Med1156469
  48. 48. Yao YG, Bravi CM, Bandelt HJ (2004) A call for mtDNA data quality control in forensic science. Forensic Sci Int 141: 1–6.YG YaoCM BraviHJ Bandelt2004A call for mtDNA data quality control in forensic science.Forensic Sci Int14116
  49. 49. Bandelt HJ, Yao YG, Salas A, Kivisild T, Bravi CM (2007) High penetrance of sequencing errors and interpretative shortcomings in mtDNA sequence analysis of LHON patients. Biochem Biophys Res Commun 352: 283–291.HJ BandeltYG YaoA. SalasT. KivisildCM Bravi2007High penetrance of sequencing errors and interpretative shortcomings in mtDNA sequence analysis of LHON patients.Biochem Biophys Res Commun352283291
  50. 50. Kong QP, Salas A, Sun C, Fuku N, Tanaka M, et al. (2008) Distilling artificial recombinants from large sets of complete mtDNA genomes. PLoS One 3: e3016.QP KongA. SalasC. SunN. FukuM. Tanaka2008Distilling artificial recombinants from large sets of complete mtDNA genomes.PLoS One3e3016